Skip to main content
SpringerLink
Log in

Long-acting risperidone of value in schizophrenia

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Damen J, Heeg BMS, Lothgren M, van Hout BA.The cost-effectiveness of risperidone long-acting injectable in Sweden. Value in Health 10: A293-A294 (plus poster) abstr. PMH21, No. 6, Nov-Dec 2007

  2. Snaterse M, Welch R.A pharmacoeconomic outcomes analysis comparing risperidone long-acting injection and conventional depot antipsychotics. Value in Health 10: A298 (plus poster) abstr. PMH34, No. 6, Nov-Dec 2007

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Long-acting risperidone of value in schizophrenia. Pharmacoecon. Outcomes News 541, 2 (2007). https://doi.org/10.2165/00151234-200705410-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200705410-00002

Keywords

Search

Navigation